 |
Glycosmedia
- weekly publication |
| |
Due to lack of funding Glycosmedia will now
be published weekly. If we can raise sufficient income we will
revert back to a daily publication. We would welcome offers of
advertising, sponsorship or educational grants. Glycosmedia now
has over 1,300 subscribers. Please contact us for information (Editor) |
| |
|
|
Clinical
Practice Consensus Guidelines 2009 |
| |
18 chapters for download (International Society
for Pediatric and Adolescent Diabetes) |
| |
|
|
Prescribing
for Diabetes in England - An Update: 2002-2008 |
| |
An analysis of volume, expenditure and trends
June 2009 (Yorkshire and Humber Public Health Observatory, UK) |
| |
|
|
The
Scottish Health Survey 2008 |
| |
Including diabetes (Scottish
Government, UK) |
| |
|
|
£19
million to the MRC/CSO Social & Public Health Sciences Unit |
| |
The SPHSU is based at the University of Glasgow
- Current research projects at the Unit focus on major health problems
that exist in developed (and also developing) countries, including
cancer, heart disease and stroke, obesity and diabetes, sexual
health and mental illness (MRC) |
| |
|
|
Welsh
Health Survey 2008 |
| |
Including statistics for diabetes (Welsh Assembly
Government) |
| |
|
|
Diabetes
and obesity rates soar |
| |
The number of people diagnosed with diabetes
in the UK has increased by more than 145,000 in the last year (Daibetes
UK) |
| |
|
|
Early
responses of insulin sensitivity to high-carbohydrate and high-fat
overfeeding |
| |
We conclude that acute bouts of overnutrition
lead to changes at the cellular level before whole-body insulin
sensitivity is altered (Nutrition and Metabolism) |
| |
|
|
Updated
prescribing information regarding acute pancreatitis and sitagliptin |
| |
The FDA is revising the prescribing information
for Januvia (sitagliptin) and Janumet (sitagliptin/metformin) to
include information on reported cases of acute pancreatitis in
patients using these products (American Diabetes Association) |
| |
|
|
Rosiglitazone
and pioglitazone |
| |
Beware macular oedema (Letter, BMJ, UK) |
| |
|
|
Boehringer
Ingelheim’s diabetes pipeline continues to advance |
| |
Following the release of linagliptin phase II
data earlier this year, Boehringer Ingelheim has now announced
the conclusion of the linagliptin pivotal phase III clinical trials
(Pharmacy Europe) |
| |
|
|
Changing
Lives: Diabetes Pill |
| |
Oramed's insulin capsule seeks to revolutionize
treatment (Video - CEO Insights, Forbes, USA) |
| |
|
|
Efficacy
and Safety of AIR Inhaled Insulin Compared to Insulin Lispro
in Patients with Type 1 Diabetes Mellitus |
| |
Insulin lispro provided lower A1C than AIR insulin,
but the difference may not be clinically relevant (Diabetes Technology & Therapeutics) |
| |
|
|
The
Diabetes Mellitus Medication Choice Decision Aid |
| |
An innovative decision aid effectively involved
patients with type 2 diabetes mellitus in decisions about their
medications but did not improve adherence or HbA1c levels (Archives
of Internal Medicine) |
| |
|
|
Cardiovascular
Manifestations of Insulin Resistance |
| |
Studies such as the Nurses' Health Study show
that even slight glucose abnormalities, namely insulin resistance,
increase the risk of myocardial infarctions, strokes, other cardiovascular
disease, and mortality (American Journal of Therapeutics) |
| |
|
|
Sanofi-aventis
launches major insulin research program in partnership with the
international scientific community |
| |
Sanofi-aventis announced that the company’s
action plan to provide methodologically robust research that will
contribute to the scientific resolution of the debate over insulin
safety, including insulin analogs and Lantus® (insulin glargine) (PharmaLive) |
| |
|
|
Influence
of insulin on cancer risk |
| |
Possible protection from cancer with metformin
examined (Endocrine Today) |
| |
|
|
Diamyd
makes investment in time-to-market |
| |
Diamyd Medical announces today that the company
has signed an agreement with Inclinix Inc., North Carolina, for
accelerated recruitment of children and adolescents recently diagnosed
with type 1 diabetes in the US Phase III study of the diabetes
vaccine (Diamyd) |
| |
|
